Heart drug digoxin tested for Alcohol-Liver damage – early trial ends early
NCT ID NCT05014087
First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This small, early-phase trial tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive either intravenous digoxin or no digoxin for up to 28 days. The study was terminated early, so the findings are limited and should be interpreted with caution.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ALCOHOLIC HEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale New Haven Hospital, Yale School of Medicine
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digoxin (intravenous)
What this could lead to
If it works, this could point toward a new way to reduce liver inflammation in severe alcohol-associated hepatitis.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. Digoxin also has known heart-related risks and requires careful monitoring.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.